Rituximab for severe immune checkpoint inhibitor-related adverse events: a multicenter case series

Key Points

• The aim is to evaluate the effectiveness of rituximab for treating severe immune checkpoint inhibitor-related adverse events.
• Multicenter case series design
• Selected cases of severe irAEs treated with rituximab
• Assessment of treatment outcomes compared to conventional therapies
• Rituximab demonstrated effectiveness in managing severe irAEs
• Improvement in symptoms was observed in patients who failed conventional immunosuppressive therapy
• Support for B-cell-targeted therapy's role in irAE management